Yuan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuan Wu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Kolasińska‐Ćwikła
Maria Sklodowska‐Curie National Research Institute of Oncology Warsaw Poland
1 shared publication - Andrew R. Moore
Liverpool University Hospitals NHS Foundation Trust Liverpool UK
1 shared publication - Chiara Maria Grana
Radiometabolic Therapy Unit, Division of Nuclear Medicine European Institute of Oncology (IEO), IRCCS Milan Italy
1 shared publication - Francesca Spada
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology (IEO), IRCCS Milan Italy
1 shared publication - Jarosław Bogdan Ćwikła
Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland
1 shared publication - Johannes Hofland
Department of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus University Medical Center , 3015 GD Rotterdam
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (4) , e70172
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [ 177 Lu ]Lu‐ DOTA ‐ TATE : A post‐authorisation safety study
A post‐authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine‐Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET) eligible for 177 Lu‐DOTATATE treatment. In a phase IV, multicentre, single‐arm, open‐label PASS, adults with somatostatin receptor‐positive GEP‐NET who were eligible for 177 Lu‐DOTATATE treatment received 1000 mL of LysaKare (monotherapy) intravenously over 4 h. The primary endpoint was the change in serum potassium levels over the course of 24 h. Secondary endpoints included the incidence of LysaKare‐related adverse events (AEs) and changes in laboratory parameters. Forty‐one patients were treated (median age, 57 years; 92.7% White and 7.3% Black; 53.7% male) and 40 completed post‐treatment follow‐up. Mean (standard deviation [SD]) serum potassium was 4.33 (0.397) mmol/L pre‐dose, increasing by 0.60 (0.666) mmol/L after 4 h (time to maximum change, range, 2–24 h) before decreasing to around the pre‐dose level: the mean (SD) increase after 24 h was 0.07 (0.396) mmol/L. Other electrolytes and blood gas components mostly showed transient changes that lasted ~24 h. A general trend of transient metabolic acidosis was also observed based on laboratory values. Serum potassium grade increased from baseline in 41.5% of patients. By comparison, five patients (12.2%) had a treatment‐related AE of hyperkalaemia (grade 3, n = 1); all resolved within 24 h, either without treatment ( n = 3) or following intravenous furosemide ( n = 2). There were no serious AEs and no AEs leading to treatment discontinuation/interruption. This PASS identified no new safety signals attributable to LysaKare. Trial registration: EudraCT, 2019‐004073‐76. Registered 20/08/2020.
- 13 April 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (4) , e70172
Open AccessThe effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [ 177 Lu ]Lu‐ DOTA ‐ TATE : A post‐authorisation safety study
A post‐authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine‐Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET) eligible for 177 Lu‐DOTATATE treatment. In a phase IV, multicentre, single‐arm, open‐label PASS, adults with somatostatin receptor‐positive GEP‐NET who were eligible for 177 Lu‐DOTATATE treatment received 1000 mL of LysaKare (monotherapy) intravenously over 4 h. The primary endpoint was the change in serum potassium levels over the course of 24 h. Secondary endpoints included the incidence of LysaKare‐related adverse events (AEs) and changes in laboratory parameters. Forty‐one patients were treated (median age, 57 years; 92.7% White and 7.3% Black; 53.7% male) and 40 completed post‐treatment follow‐up. Mean (standard deviation [SD]) serum potassium was 4.33 (0.397) mmol/L pre‐dose, increasing by 0.60 (0.666) mmol/L after 4 h (time to maximum change, range, 2–24 h) before decreasing to around the pre‐dose level: the mean (SD) increase after 24 h was 0.07 (0.396) mmol/L. Other electrolytes and blood gas components mostly showed transient changes that lasted ~24 h. A general trend of transient metabolic acidosis was also observed based on laboratory values. Serum potassium grade increased from baseline in 41.5% of patients. By comparison, five patients (12.2%) had a treatment‐related AE of hyperkalaemia (grade 3, n = 1); all resolved within 24 h, either without treatment ( n = 3) or following intravenous furosemide ( n = 2). There were no serious AEs and no AEs leading to treatment discontinuation/interruption. This PASS identified no new safety signals attributable to LysaKare. Trial registration: EudraCT, 2019‐004073‐76. Registered 20/08/2020.